Zoetis Inc.

(New York Stock Exchange)
Back to all articles
Neutral 0

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)

AI-generated analysis

πŸ₯ Analysts show mixed sentiment on three healthcare companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT), and GoodRx Holdings (GDRX).

πŸ’° Morgan Stanley maintained a Buy rating on Zoetis with a $115.00 price target, up from its Thursday close of $75.48.

πŸ“ˆ The Street consensus for Zoetis is Moderate Buy with an average price target of $132.58, implying 78.1% upside.

⚠️ Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics with a $19.00 price target.

🎯 Sarepta Therapeutics consensus remains Hold with an average price target of $21.64, suggesting 12.0% upside.

πŸ’Ή Truist Financial analyst Jailendra Singh maintained a Hold rating on GoodRx Holdings at its Thursday close of $2.49.

πŸ“‰ The analyst consensus for GoodRx is Hold with a $3.09 price target, implying 18.4% potential upside.

⚑ Recent upgrades and downgrades from firms like TipRanks – xAI and DeepSeek have influenced the price targets for SRPT and GDRX.

Bullish Signals
  • Analysts maintain a Buy rating on Zoetis (ZTS) with an average price target of $132.58, representing a 78.1% upside from current levels.
  • Erin Wright from Morgan Stanley maintained a Buy rating on Zoetis with a specific price target of $115.00, which is significantly above the recent closing price of $75.48.
  • TipRanks highlights that Erin Wright is a 5-star analyst with an impressive average return of 14.7% and a 62.5% success rate covering Healthcare stocks.
  • TipRanks upgraded Zoetis to Buy with a $127.00 price target in a report issued on May 6, reinforcing positive momentum for the stock.
  • Analyst consensus on Sarepta Therapeutics (SRPT) shows a Hold rating with an average price target of $21.64, implying a 12.0% upside from current levels.
  • Sarepta Therapeutics received a Hold upgrade with a $22.50 price target in a report issued on May 5 by TipRanks – xAI.
  • GoodRx Holdings (GDRX) has an analyst consensus of Hold with a price target of $3.09, implying a 18.4% upside from current levels.
  • The stock market generally favors Zoetis over Sarepta Therapeutics and GoodRx Holdings based on analyst buy ratings and higher implied upside potential.
Risk Factors
  • Analyst Erin Wright from Morgan Stanley maintains a Buy rating with a price target of $115.00, yet the company's shares closed last Thursday at $75.48, suggesting significant downside potential remains even with bullish analyst coverage.
  • The analyst consensus for Sarepta Therapeutics is a Hold with an average price target of $21.64, implying only 12.0% upside from current levels, indicating limited growth expectations among investors.
  • Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics today and set a price target of $19.00, nearly flat with the company's closing price of $18.68.
  • Truist Financial analyst Jailendra Singh has zero stars on TipRanks.com and an average return of -12.4% over his career, raising concerns about the reliability of coverage on GoodRx Holdings despite a Hold rating.
  • GoodRx Holdings has an analyst consensus of Hold with a price target of $3.09, yet recent downgrades to a $3.00 price target suggest growing skepticism among analysts regarding its future performance.
  • The article notes that the investor sentiment toward Tech stocks is overly optimistic ('partying like it's 1999'), suggesting potential market risk for healthcare companies as investors may overreact to positive earnings data.
Full Analysis
Analyst sentiment remains mixed for a trio of healthcare sector companies, with Zoetis (ZTS) receiving the most positive attention. Erin Wright at Morgan Stanley maintained a Buy rating on ZTS, setting a price target of $115.00 against a share price closing at $75.48 last Thursday. TipRanks data indicates a moderate buy consensus for ZTS with an average analyst price target of $132.58, suggesting 78.1% upside from current levels; this follows a previous Buy upgrade by xAI in late April to a $127.00 target. Gavin Clark-Gartner at Evercore ISI holds Sarepta Therapeutics (SRPT) with a price target of $19.00, while the broader analyst consensus rates SRPT as Hold with an average target of $21.64, implying 12.0% upside from the closing price of $18.68. For GoodRx Holdings (GDRX), Jailendra Singh at Truist Financial maintains a Hold rating with a price target of $3.09, which represents 18.4% upside from its Thursday closing price of $2.49. The consensus for GDRX remains Hold according to TipRanks data. The article notes that these insights come via TipRanks, aggregating analyst actions and targets for the three healthcare names, highlighting divergent expectations within the broader Healthcare sector coverage today.